Peggy L. Lin

1.0k total citations
33 papers, 708 citations indexed

About

Peggy L. Lin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Peggy L. Lin has authored 33 papers receiving a total of 708 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Peggy L. Lin's work include Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (8 papers). Peggy L. Lin is often cited by papers focused on Advanced Breast Cancer Therapies (11 papers), Cancer Treatment and Pharmacology (10 papers) and HER2/EGFR in Cancer Research (8 papers). Peggy L. Lin collaborates with scholars based in United States, United Kingdom and Switzerland. Peggy L. Lin's co-authors include Amy S. Paller, Marcia F.T. Rupnow, Jason C. Cole, Jakob Bue Bjørner, Gene V. Wallenstein, Samir H. Mody, Catherine Tak Piech, Marie C. Martin, Magdalene Dohil and Lawrence F. Eichenfield and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American Academy of Dermatology.

In The Last Decade

Peggy L. Lin

32 papers receiving 667 citations

Peers

Countries citing papers authored by Peggy L. Lin

Since Specialization

Citations

This map shows the geographic impact of Peggy L. Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peggy L. Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peggy L. Lin more than expected).

Fields of papers citing papers by Peggy L. Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peggy L. Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peggy L. Lin. The network helps show where Peggy L. Lin may publish in the future.

Co-authorship network of co-authors of Peggy L. Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Peggy L. Lin. A scholar is included among the top collaborators of Peggy L. Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peggy L. Lin. Peggy L. Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Matching‐adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone with daratumumab plus lenalidomide and dexamethasone in relapsed multiple myeloma 2023 ·Cancer Medicine ·Joshua Richter, Peggy L. Lin, (unknown), Patricia Guyot, (unknown), Zheng‐Yi Zhou, Mark Sievert, (unknown)	6
2	The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis 2019 ·Health Economics Review ·(unknown), (unknown), (unknown), Peggy L. Lin, Clare Rowntree, Vaskar Saha	8
3	Effectiveness of Everolimus Versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2− mBC Patients With Multiple Metastatic Sites 2016 ·Clinical Therapeutics ·Nanxin Li, Yanni Hao, Jipan Xie, Peggy L. Lin, (unknown), (unknown), Eric Q. Wu	2
4	Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer 2015 ·Current Medical Research and Opinion ·Nanxin Li, Yanni Hao, Jipan Xie, Peggy L. Lin, Zhou Zhou, Yichen Zhong, James Signorovitch, Eric Q. Wu	4
5	Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey 2015 ·Cancer Medicine ·Peggy L. Lin, Yanni Hao, Jipan Xie, Nanxin Li, Yichen Zhong, Zhou Zhou, James Signorovitch, Eric Q. Wu	11
6	Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US 2015 ·Experimental Hematology and Oncology ·Jipan Xie, Yanni Hao, Nanxin Li, Peggy L. Lin, (unknown), (unknown), Eric Q. Wu	13
7	Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States 2015 ·Expert Opinion on Pharmacotherapy ·Michael K. Wong, Eric Jonasch, Sumanta K. Pal, James Signorovitch, Peggy L. Lin, Xufang Wang, Zhimei Liu, (unknown), Jeffrey A. Scott, Daniel J. George, Nicholas J. Vogelzang	5
8	Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2− metastatic breast cancer: a retrospective chart review in community oncology practices in the US 2015 ·Current Medical Research and Opinion ·Jipan Xie, Yanni Hao, Nanxin Li, Peggy L. Lin, (unknown), (unknown), James Signorovitch, Eric Q. Wu, Denise A. Yardley	10
9	Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA 2015 ·Expert Opinion on Pharmacotherapy ·Peggy L. Lin, Yanni Hao, Jipan Xie, Nanxin Li, (unknown), (unknown), Eric Q. Wu	3
10	Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR ⁺ /HER2 ^- metastatic breast cancer 2015 ·Journal of Comparative Effectiveness Research ·Yanni Hao, Peggy L. Lin, Jipan Xie, Nanxin Li, (unknown), (unknown), Eric Q. Wu, (unknown)	2
11	Associations Between Joint Damage and Quality of Life Among Patients with Severe Hemophilia a in the 3-Year Spinart Trial 2014 ·Blood ·Jennifer Pocoski, Peggy L. Lin, (unknown), Sneha S. Kelkar, (unknown), Ella X. Du, Thomas J. Humphries, Jipan Xie	1
12	Treatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010) 2014 ·Current Medical Research and Opinion ·Alexander R. Macalalad, Yanni Hao, Peggy L. Lin, James Signorovitch, Eric Q. Wu, (unknown), Zhou Zhou, Caroline Kelley	25
13	Sequential use of targeted therapies for metastatic renal cell carcinoma: A physician survey and chart review of community oncology practices in the United States. 2013 ·Journal of Clinical Oncology ·Nicholas J. Vogelzang, James Signorovitch, Peggy L. Lin, Zhimei Liu, Kenneth W. Culver, Jeffrey A. Scott, Sumanta K. Pal, Eric Jonasch	4
14	Outcomes of second-targeted therapy for mRCC: A retrospective chart review of community practices in the United States. 2013 ·Journal of Clinical Oncology ·Eric Jonasch, James Signorovitch, Peggy L. Lin, Zhimei Liu, Kenneth W. Culver, Sumanta K. Pal, Jeffrey A. Scott, Nicholas J. Vogelzang	1
15	Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment 2007 ·Quality of Life Research ·Jason C. Cole, Peggy L. Lin, Marcia F.T. Rupnow	76
16	Tacrolimus Ointment is Effective for Psoriasis on the Face and Intertriginous Areas in Pediatric Patients 2007 ·Pediatric Dermatology ·(unknown), (unknown), Peggy L. Lin, (unknown), Amy S. Paller	71
17	Interpreting score differences in the SF-36 Vitality scale: using clinical conditions and functional outcomes to define the minimally important difference 2007 ·Current Medical Research and Opinion ·Jakob Bue Bjørner, Gene V. Wallenstein, Marie C. Martin, Peggy L. Lin, (unknown), Catherine Tak Piech, Samir H. Mody	145
18	The epidemiology of molluscum contagiosum in children 2005 ·Journal of the American Academy of Dermatology ·Magdalene Dohil, Peggy L. Lin, James Lee, Anne W. Lucky, Amy S. Paller, Lawrence F. Eichenfield	92
19	Tacrolimus ointment promotes repigmentation of vitiligo in children: A review of 57 cases 2004 ·Journal of the American Academy of Dermatology ·Nanette B. Silverberg, Peggy L. Lin, (unknown), (unknown), Anthony J. Mancini, Annette Wagner, Sarah L. Chamlin, Amy S. Paller	98
20	Changing paradigms in dermatology: antivirals in dermatology 2003 ·Clinics in Dermatology ·Peggy L. Lin, Gisela Torres, Stephen K. Tyring	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact